Menu Search
Equities

Genscript Biotech Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
G51:MUN

Genscript Biotech Corp

Actions
  • Price (EUR)1.35
  • Today's Change0.023 / 1.73%
  • Shares traded--
  • 1 Year change+0.86%
  • Beta0.6862
Data delayed at least 15 minutes, as of Feb 11 2026 07:09 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Genscript Biotech Corp is an investment holding company principally engaged in the manufacture and sale of life science research products and services. The Company operates its businesses through five segments. The Life-science Services and Products segment provides comprehensive research services and products. The Biologics Development Services segment provides comprehensive services to help biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and gene, cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment provides industrial enzyme development and production through non-pathogenic microbial strains constructed using genetic engineering. The Cell Therapy segment discovers and develops CAR-T therapies for the treatment of liquid and solid tumors. The Operation segment provides shared services to other segments. The Company mainly operates its businesses in the domestic and overseas markets.

  • Revenue in HKD (TTM)4.31bn
  • Net income in HKD644.46m
  • Incorporated2015
  • Employees5.77k
  • Location
    Genscript Biotech CorpNo. 28Yongxi Road, Jiangning Science ParkNANJING ChinaCHN
  • Phone+86 2 558897288
  • Fax+86 2 558897288
  • Websitehttps://www.genscript.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.